Preoperative Platelet Count Associates with Survival and Distant Metastasis in Surgically Resected Colorectal Cancer Patients
- 222 Downloads
Platelets have been implicated in cancer metastasis and prognosis. No population-based study has been reported as to whether preoperative platelet count directly predicts metastatic recurrence of colorectal cancer (CRC) patients.
Using a well-characterized cohort of 1,513 surgically resected CRC patients, we assessed the predictive roles of preoperative platelet count in overall survival, overall recurrence, as well as locoregional and distant metastatic recurrences.
Patients with clinically high platelet count (≥400 × 109/L) measured within 1 month before surgery had a significantly unfavorable survival (hazard ratio [HR] = 1.66, 95 % confidence interval [CI] 1.34–2.05, P = 2.6 × 10−6, Plog rank = 1.1 × 10−11) and recurrence (HR = 1.90, 1.24–2.93, P = 0.003, Plog rank = 0.003). The association of platelet count with recurrence was evident only in patients with metastatic (HR = 2.81, 1.67–4.74, P = 1.1 × 10−4, Plog rank = 2.6 × 10−6) but not locoregional recurrence (HR = 0.59, 95 % CI 0.21–1.68, P = 0.325, Plog rank = 0.152). The findings were internally validated through bootstrap resampling (P < 0.01 at 98.6 % of resampling). Consistently, platelet count was significantly higher in deceased than living patients (P < 0.0001) and in patients with metastatic recurrence than locoregional (P = 0.004) or nonrecurrent patients (P < 0.0001). Time-dependent modeling indicated that the increased risks for death and metastasis associated with elevated preoperative platelet counts persisted up to 5 years after surgery.
Our data demonstrated that clinically high level of preoperative platelets was an independent predictor of CRC survival and metastasis. As an important component of the routinely tested complete blood count panel, platelet count may be a cost-effective and noninvasive marker for CRC prognosis and a potential intervention target to prevent metastatic recurrence.
KeywordsPlatelet Thrombocytosis CRC Survival Recurrence Metastasis
- 3.Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol: official j Am Soc Clin Oncol. 2004;22:1420–9.CrossRefGoogle Scholar
- 5.Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol: official j Am Soc Clin Oncol. 2006;24:386–93.CrossRefGoogle Scholar
- 16.Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nature reviews. Cancer. 2011;11:123–34.Google Scholar
- 25.Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol: official j Am Soc Clin Oncol. 1991;9:1639–49.Google Scholar
- 32.Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program 2009:159–67.Google Scholar